1. [Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
- Author
-
Miyashita K, Fujimaki K, and Ishigatsubo Y
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Benzamides, Female, Humans, Imatinib Mesylate, Middle Aged, Piperazines administration & dosage, Piperazines adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Vomiting chemically induced, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Piperazines therapeutic use, Pyrimidines therapeutic use
- Abstract
A 57-year-old woman was diagnosed as in the chronic myeloid leukemia-chronic phase. Imatinib mesylate(IM)was initiated at 400 mg daily. She achieved complete cytogenetic response at 3 months, and major molecular response at 10 months. IM was reduced to 300 mg daily at 12 months because of grade 1 nausea. IM was reduced to 300 mg for 5 days per week by her demand at 22 months. Major molecular response was maintained with 300 mg of IM for 3 days per week at 77 months. The intermittent IM therapy might be useful for CML patients who cannot tolerate the standard dose of IM.
- Published
- 2013